Daxor CorpDXR
Price$10.98

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $25KTTM through 31 Dec 2011
Net Income $9.2MTTM through 31 Dec 2011

Margins

Current

Returns

20.0%ROE
19.9%ROA

Multi-Year Trend

Revenue
'10'11
FY2011: $1.4M

Dividend

$0.03Per share, FY20180.27%Yield

Segment Performance

SegmentRevenueYoYOutlook
Operating Division+45.0%
View details

Daxor received FDA 510(k) clearance in August 2025 for its next-generation portable Blood Volume Analyzer, which delivers results three times faster. The company is expanding its commercial sales team and production facilities to scale placements.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.